Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokline

An immunogenic composition suitable for administration to a human, comprising an effective combination of:

• a) a first population of tumor cells autologous to the human, or progeny of such cells, and
• b) a second population of tumor cells allogeneic to the human genetically altered to produce a cytokine at an elevated level, or progeny of such cells.

An immunogenic composition suitable for administration to a human, comprising a tumor associated antigen and a population of cells expressing a transmembrane cytokine at a level sufficient to enhance an immune response to the tumor associated antigen.

A brain cancer cell designated ACBT, and the progeny thereof.

A method of stimulating an anti-tumor immunological response in a human, comprising the steps of:

• a) forming a cell mixture by mixing together in vitro a tumor-associated antigen obtained from a cell autologous to the human with a cell allogeneic to the human, wherein the allogeneic cell has been genetically altered to produce a cytokine at an elevated level;
• and
• b) administering an immunogenic amount of the cell mixture to the human.

A method of treating a neoplastic disease in a human, comprising the steps of:

• a) forming a cell mixture by mixing together in vitro a tumor-associated antigen obtained from a cell autologous to the human with a cell allogeneic to the human, wherein the allogeneic cell has been genetically altered to produce a cytokine at an elevated level;
• and
• b) administering an effective amount of the cell mixture to the human.